Format

Send to

Choose Destination
Psychopharmacology (Berl). 2016 Sep;233(17):3259-67. doi: 10.1007/s00213-016-4364-0. Epub 2016 Jun 29.

A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment.

Author information

1
Department of Psychiatry, School of Medicine, Clinical Hospital Centre Zagreb, University of Zagreb, Zagreb, Croatia.
2
Rudjer Boskovic Institute, Division of Molecular Medicine, Bijenicka cesta 54, 10 000, Zagreb, Croatia.
3
Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
4
Clinics for Psychiatry Vrapce, Zagreb, Croatia.
5
Rudjer Boskovic Institute, Division of Molecular Medicine, Bijenicka cesta 54, 10 000, Zagreb, Croatia. npivac@irb.hr.

Abstract

BACKGROUND:

Various antidepressants occupy brain serotonin transporter (SERT), decrease platelet serotonin (5-HT) concentration, and normalize reduced plasma brain-derived neurotrophic factor (BDNF) concentrations in depressed patients. Vortioxetine is a recently introduced antidepressant with a multimodal mechanism of action. In addition to SERT inhibition, vortioxetine acts via different 5-HT receptors. To further elucidate its mechanism of action, we have investigated the effects of vortioxetine on platelet 5-HT and plasma BDNF concentrations in patients with major depression.

METHODS:

Platelet 5-HT and plasma BDNF concentrations were determined in 44 healthy subjects at baseline and in 44 depressed patients before and after 4 weeks of treatment with vortioxetine (5-15 mg daily). Platelet 5-HT concentration was determined using the ortho-phthalaldehyde-enhanced fluorometric method, and plasma BDNF concentration using a commercial enzyme-linked immunosorbent assay (Quantikine ELISA, R&D Systems).

RESULTS:

At baseline, platelet 5-HT concentrations did not differ between depressed and control subjects, but plasma BDNF values were lower (p = 0.011; ω = 0.80) in depressed patients than in healthy subjects. Vortioxetine treatment significantly (p < 0.0001; ω = 0.80) decreased platelet 5-HT concentration and significantly (p = 0.004; ω = 0.80) increased plasma BDNF concentration in depressed patients compared to their baseline values. Age, gender, and smoking were not significantly associated with platelet 5-HT and plasma BDNF concentrations.

CONCLUSION:

Despite a novel mechanism of action, vortioxetine shares some common effects with other antidepressants. This study is the first to show that, in addition to clinical improvement, 4 weeks of treatment with vortioxetine (5-15 mg daily), decreased platelet 5-HT and increased plasma BDNF concentrations in depressed patients.

KEYWORDS:

Antidepressants; Depression; Plasma BDNF; Platelet serotonin; Vortioxetine

PMID:
27356518
DOI:
10.1007/s00213-016-4364-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center